Use access key #2 to skip to page content.

Bilifuduo (96.37)

Potential in Alexion Pharmaceuticals



May 31, 2012 – Comments (0) | RELATED TICKERS: ALXN

Alexion Pharmaceuticals is a biopharmaceutical company with a $17.28B market cap that generates revenues through its development of "orphan drugs" for ultra-rare and severe disorders. As the company increasingly expands the uses of its marquee drug Soliris and develops its other products such as asfotase alfa, it will most likely continue its positive stock performance and strong company growth. Full article: here.

0 Comments – Post Your Own

Featured Broker Partners